Microdose, Author at Microdose

Author at Microdose

Microdose

At our core, we champion integrity, diversity, and objectivity, providing trusted content that unites a wide array of experts and fosters unbiased opinions, ultimately empowering the psychedelic medicine community to flourish and make a positive impact on the world.

Press Releases

7 Jun 2021

Lobe Sciences to Present at the LD Micro Invitational XI

By Microdose

Press Releases

3 Jun 2021

Psyched Wellness Hires Ad Agency, dacs Marketing to Build the Branding and Marketing Strategy for AME-1

Toronto, Ontario–(Newsfile Corp....

By Microdose

Press Releases

2 Jun 2021

BetterLife Pharma Appoints Henri Sant-Cassia of The Conscious Fund to its Board of Directors

VANCOUVER, British Columbia, June 02, 2021 (GLOBE NEWSWIRE) — BetterLife Pharma Inc....

By Microdose

Press Releases

1 Jun 2021

Tryp Therapeutics to Present at the H.C. Wainwright Psychedelics Conference

San Diego, California–(Newsfile Corp....

By Microdose

Join Our Newsletter for Exclusive Updates, Stories, and More

Press Releases

28 May 2021

NeonMind to Commence Trading on the OTCQB Venture Market

Vancouver, British Columbia–(Newsfile Corp....

By Microdose

Press Releases

26 May 2021

NeonMind Announces Creation of Medical Clinics Advisory Board to Guide Planning and Operation of Company-Branded Clinics Across Canada

Vancouver, British Columbia–(Newsfile Corp....

By Microdose

Press Releases

25 May 2021

Tryp Therapeutics Partners with Alcami for Proprietary Formulations

By Microdose

Press Releases

19 May 2021

Lobe Sciences Secures Production and Supply Agreement for Vitamind Consumer Packaged Goods Products

By Microdose

Press Releases

18 May 2021

Entheon Biomedical Announces DMT Drug Supply Agreement with Ofichem Group

Vancouver, British Columbia–(Newsfile Corp....

By Microdose

Follow us on social

Latest News

Trump’s Psychedelic Fast-Track Order Changes the Timeline. It Also Redraws the Competitive Map.

AbbVie Withdraws Patent Challenge, Clearing Path for Enveric’s Psychedelic IP Strategy

Breaking: Enveric Reports New Mechanistic Data Supporting Non-Hallucinogenic Neuroplastogen Strategy

17 Dec 2025

Psychedelics in 2025: A Year of Proof, Pullback, and a Clearer Path Forward

If 2024 was the year the psychedelic field learned how hard “approval ready” really is, 2025 was the year it began behaving accordingly. The past twelve months were less about...

By Madison Roberts

26 Nov 2025

Delix Therapeutics Reports Strong Phase Ib Results

Delix Therapeutics recently announced compelling data from a Phase Ib trial of DLX-001 (zalsupindole), a non-hallucinogenic neuroplastogen. According to the company’s release, DLX-001 produced robust biomarker signals (quantitative EEG and...

By Madison Roberts

19 Nov 2025

Childhood Trauma’s Role in Men’s Substance Use Disorders

Childhood trauma leaves a deeper imprint on men’s lives than most realize—and for many, it becomes the hidden engine driving substance use disorders. Research shows that emotional abuse, physical violence,...

By Madison Roberts

19 Nov 2025

Human-Centered AI in Healthcare

Artificial intelligence is redefining modern healthcare, offering powerful tools that enhance diagnosis, expedite drug discovery, and enable truly personalized treatment. As health systems struggle with rising costs, aging populations, and...

By Madison Roberts

16 Oct 2025

Enveric Biosciences Doubles Down on IP Strength as Psychedelic Biotech Sector Heats Up

As Big Pharma makes billion-dollar bets in the evolving landscape of neuropsychiatric therapeutics, Enveric Biosciences (NASDAQ: ENVB) is carving out a formidable position — not by chasing headlines, but by...

By Madison Roberts

15 Oct 2025

The IP Battle Behind the $1.2B Psychedelic Acquisition—and Why Enveric Biosciences Is a Name to Watch

Take Enveric Biosciences (NASDAQ: ENVB), a company that’s been flying under the radar while building an IP fortress around a novel class of non-hallucinogenic neuroplastogens. Now, that fortress is being...

By Madison Roberts

WordPress Ads

No Result

View All Result

Author at Microdose

Microdose

At our core, we champion integrity, diversity, and objectivity, providing trusted content that unites a wide array of experts and fosters unbiased opinions, ultimately empowering the psychedelic medicine community to flourish and make a positive impact on the world.

Press Releases

Lobe Sciences to Present at the LD Micro Invitational XI

Press Releases

Psyched Wellness Hires Ad Agency, dacs Marketing to Build the Branding and Marketing Strategy for AME-1

Press Releases

BetterLife Pharma Appoints Henri Sant-Cassia of The Conscious Fund to its Board of Directors

Press Releases

Tryp Therapeutics to Present at the H.C. Wainwright Psychedelics Conference

Join Our Newsletter for Exclusive Updates, Stories, and More

Press Releases

NeonMind to Commence Trading on the OTCQB Venture Market

Press Releases

NeonMind Announces Creation of Medical Clinics Advisory Board to Guide Planning and Operation of Company-Branded Clinics Across Canada

Press Releases

Tryp Therapeutics Partners with Alcami for Proprietary Formulations

Press Releases

Lobe Sciences Secures Production and Supply Agreement for Vitamind Consumer Packaged Goods Products

Press Releases

Entheon Biomedical Announces DMT Drug Supply Agreement with Ofichem Group

Follow us on social

Latest News

Trump’s Psychedelic Fast-Track Order Changes the Timeline. It Also Redraws the Competitive Map.

AbbVie Withdraws Patent Challenge, Clearing Path for Enveric’s Psychedelic IP Strategy

Breaking: Enveric Reports New Mechanistic Data Supporting Non-Hallucinogenic Neuroplastogen Strategy

You Might Also Like

Psychedelics in 2025: A Year of Proof, Pullback, and a Clearer Path Forward

Delix Therapeutics Reports Strong Phase Ib Results

Childhood Trauma’s Role in Men’s Substance Use Disorders

Human-Centered AI in Healthcare

Enveric Biosciences Doubles Down on IP Strength as Psychedelic Biotech Sector Heats Up

The IP Battle Behind the $1.2B Psychedelic Acquisition—and Why Enveric Biosciences Is a Name to Watch